TY - JOUR
T1 - Cardiac Computed Tomography in Cardio-Oncology
T2 - JACC: CardioOncology Primer
AU - Lopez-Mattei, Juan C.
AU - Yang, Eric H.
AU - Ferencik, Maros
AU - Baldassarre, Lauren A.
AU - Dent, Susan
AU - Budoff, Matthew J.
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/12
Y1 - 2021/12
N2 - Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosclerotic cardiovascular disease (ASCVD), valvular heart disease, pericardial disease, and arrhythmias. Cardiac computed tomography (CT) can be helpful in identifying both clinical and subclinical ASCVD in cancer patients and survivors. Radiation therapy treatment planning CT scans and cancer staging/re-staging imaging studies can quantify calcium scores which can identify pre-existing subclinical ASCVD. Cardiac CT can be helpful in the evaluation of cardiac tumors and pericardial diseases, especially in patients who cannot tolerate or have a contraindication to cardiac magnetic resonance. In this review, we describe the optimal utilization of cardiac CT in cancer patients, including risk assessment for ASCVD and identification of cancer treatment-related cardiovascular toxicity.
AB - Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosclerotic cardiovascular disease (ASCVD), valvular heart disease, pericardial disease, and arrhythmias. Cardiac computed tomography (CT) can be helpful in identifying both clinical and subclinical ASCVD in cancer patients and survivors. Radiation therapy treatment planning CT scans and cancer staging/re-staging imaging studies can quantify calcium scores which can identify pre-existing subclinical ASCVD. Cardiac CT can be helpful in the evaluation of cardiac tumors and pericardial diseases, especially in patients who cannot tolerate or have a contraindication to cardiac magnetic resonance. In this review, we describe the optimal utilization of cardiac CT in cancer patients, including risk assessment for ASCVD and identification of cancer treatment-related cardiovascular toxicity.
KW - atherosclerotic cardiovascular disease
KW - calcium score cardio-oncology
KW - carcinoid syndrome
KW - cardiotoxicity
KW - cardiovascular computed tomography
KW - radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85120846524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120846524&partnerID=8YFLogxK
U2 - 10.1016/j.jaccao.2021.09.010
DO - 10.1016/j.jaccao.2021.09.010
M3 - Review article
AN - SCOPUS:85120846524
SN - 2666-0873
VL - 3
SP - 635
EP - 649
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 5
ER -